Secondary analysis of the Canakinumab Anti-Inflammatory Thrombosis Outcome Study showed a significant trend toward decreased HF events with IL-1β blockade in patients without HF but with prior myocardial infarction (MI; ref. 6 ).
← all excerpts
Association of immune cell subsets with cardiac mechanics in the Multi-Ethnic Study of Atherosclerosis.
1
—
—